Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115250) titled 'Phase IB/II clinical study of the safety, tolerability and efficacy of HRS-4642 in combination with other anti-tumor drugs in subjects with solid tumors' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Peking Union Medical College Hospital
Condition:
Subjects with locally advanced or metastatic pancreatic cancer with KRAS G12D gene mutations
Intervention:
Control group:HRS-4642 United AG
Recruitment Status: Not Recruiting
Phase: 1-2
Date of First Enrollment: 2025-12-26
Target Sample Size: Control group:30;Experimental group:30;
Countries of Recruitment:
C...